CFL1 and neoplasm: Based on this regulatory mechanism, systemic co‐delivery of siCFL1 and sorafenib with reduction‐responsive nanoparticles can effectively silence CFL1 expression and significantly inhibit HCC patient‐derived xenografts tumor growth.